{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:46:15Z","timestamp":1793015175455,"version":"4.5.0"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T00:00:00Z","timestamp":1487808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            SCY-078 is an orally bioavailable \u00df-1,3-glucan synthesis inhibitor (GSI) and the first-in-class of structurally novel triterpene antifungals in clinical development for treating candidemia and invasive candidiasis.\n            <jats:italic>In vitro<\/jats:italic>\n            susceptibilities by broth microdilution, antifungal carryover, and time-kill dynamics were determined for three reference (ATCC) strains (\n            <jats:named-content content-type=\"genus-species\">Candida albicans<\/jats:named-content>\n            90028,\n            <jats:named-content content-type=\"genus-species\">Candida parapsilosis<\/jats:named-content>\n            90018, and\n            <jats:named-content content-type=\"genus-species\">Candida tropicalis<\/jats:named-content>\n            750), a quality-control (QC) strain (\n            <jats:named-content content-type=\"genus-species\">Candida krusei<\/jats:named-content>\n            6258), and four other strains (\n            <jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>\n            MYA-2732, 64124, and 76485 and\n            <jats:named-content content-type=\"genus-species\">Candida glabrata<\/jats:named-content>\n            90030). Caspofungin (CASP), fluconazole (FLC), and voriconazole (VRC) were comparators. For time-kill experiments, SCY-078 and CASP were evaluated at 0.25, 1, 2, 4, 8, and 16 times the MIC\n            <jats:sub>80<\/jats:sub>\n            , and FLU and VRC were evaluated at 4\u00d7 MIC\n            <jats:sub>80<\/jats:sub>\n            . The time to reach 50%, 90%, and 99.9% reduction in the number of CFUs from the starting inoculum was determined. Net change in the number of CFU per milliliter was used to determine 50% and 90% effective concentrations and maximum effect (EC\n            <jats:sub>50<\/jats:sub>\n            , EC\n            <jats:sub>90<\/jats:sub>\n            , and\n            <jats:italic>E<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            , respectively). The SCY-078 MIC range was between 0.0625 and 1 \u03bcg\/ml and generally similar to that of CASP. Antifungal carryover was not observed for SCY-078. SCY-078 was fungicidal against seven isolates at \u22654\u00d7 MIC (kill of \u22653 log\n            <jats:sub>10<\/jats:sub>\n            ) and achieved a 1.7-log\n            <jats:sub>10<\/jats:sub>\n            reduction in CFU count\/milliliter against\n            <jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>\n            90028. CASP behaved similarly against each isolate and achieved a 1.5-log\n            <jats:sub>10<\/jats:sub>\n            reduction in the number of CFU\/milliliter against\n            <jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>\n            90028. Reductions of 50% in CFU count\/milliliter were achieved rapidly (1 to 2.8 h); fungicidal endpoints were reached at 12.1 to 21.8 h at \u22654\u00d7 MIC. EC\n            <jats:sub>90<\/jats:sub>\n            was reached at \u223c5\u00d7 MIC at each time point to 24 h. The EC\n            <jats:sub>50<\/jats:sub>\n            and EC\n            <jats:sub>90<\/jats:sub>\n            values were generally similar (8 to 24 h). Time-kill behavior of CASP was similar to that of SCY-078. FLC and VRC were fungistatic. Overall, SCY-078 has primarily fungicidal activity against\n            <jats:named-content content-type=\"genus-species\">Candida<\/jats:named-content>\n            spp. and behaved comparably to CASP.\n          <\/jats:p>","DOI":"10.1128\/aac.01961-16","type":"journal-article","created":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T02:30:27Z","timestamp":1484015427000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":84,"title":["SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies"],"prefix":"10.1128","volume":"61","author":[{"given":"Bernard","family":"Scorneaux","sequence":"first","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Angulo","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katyna","family":"Borroto-Esoda","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ghannoum","sequence":"additional","affiliation":[{"name":"Case Western University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Peel","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Wring","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780701218689"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902911440"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-008-1338-7"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868140-00002"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2011.23.6.319"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.11.001"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000111"},{"key":"e_1_3_2_9_2","volume-title":"Antibiotic resistance threats in the United States","author":"CDC","year":"2013","unstructured":"CDC. 2013. Antibiotic resistance threats in the United States,2013. CDC,Atlanta, GA."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks466"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02145-13"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04445-14"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2012.05.031"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.6.927"},{"key":"e_1_3_2_15_2","volume-title":"CLSI document M27-A3","author":"CLSI","year":"2008","unstructured":"CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard,3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute,Wayne, PA.","edition":"3"},{"key":"e_1_3_2_16_2","volume-title":"CLSI document M27-S4","author":"CLSI","year":"2012","unstructured":"CLSI. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute,Wayne, PA."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.12.3846-3853.2002"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00130-8"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(96)00202-7"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1917-1920.2000"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02068-16"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.5.1094-1097.1995"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01961-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01961-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:47:16Z","timestamp":1645476436000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01961-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1128\/AAC.01961-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.01961-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"2016-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01961-16"}}